Who Buys Dasatinib from India — 177 Importers Behind a $16.4M Market

The importation of Dasatinib from India involves various buyer segments, each with distinct purchasing behaviors:

• Pharmaceutical Companies: Entities like TARO PHARMACEUTICALS INC (Canada), DR. REDDY'S LABORATORIES INC (United States), and AUROBINDO PHARMA USA INC (United States) are prominent buyers. These companies procure Dasatinib to expand their oncology portfolios, ensuring a steady supply to meet market demand. Their purchasing patterns typically involve large, consistent orders to maintain inventory levels and fulfill contractual obligations.

• Distributors: Organizations such as YUSEN LOGISTICS BENELUX BELGIUM (Belgium) function as intermediaries, facilitating the distribution of Dasatinib to various healthcare providers. Their procurement is characterized by bulk purchases, aligning with market demand and distribution agreements.

• Healthcare Providers: Entities like SUN PHARMA ANZ PTY LTD (Australia) may represent hospital groups or healthcare networks that import Dasatinib directly to ensure timely availability for patient treatment. Their buying behavior is influenced by patient needs, treatment protocols, and budget considerations, often resulting in periodic, substantial orders.

• Government Procurement Agencies: Organizations such as NUEVOS ETICOS NEOETHICALS S A (Guatemala) may engage in tender-based purchasing to supply public healthcare systems. Their procurement processes are typically governed by national healthcare policies, budget allocations, and the objective of providing affordable medications to the population.

Understanding these segments is crucial for tailoring market strategies, forecasting demand, and ensuring efficient supply chain management.

Import regulations for Dasatinib vary across the top importing countries:

• United States:
• Regulatory Authority: Food and Drug Administration (FDA).
• Import Registration Process: Importers must ensure that Dasatinib complies with FDA regulations, including proper labeling and registration. Affirmation of Compliance codes, such as Drug Registration Number (REG) and Drug Listing Number (DLS), are required to facilitate the import process.
• Estimated Timeline for Registration: The timeline can vary; however, providing accurate Affirmation of Compliance codes can expedite the initial screening and review process.
• Import Tariff/Duty for HS 30049049: Specific tariff rates for this HS code should be verified with the U.S. International Trade Commission or Customs and Border Protection, as they are subject to change.

• Canada:
• Regulatory Authority: Health Canada.
• Import Registration Process: Importers must comply with the Food and Drug Regulations, ensuring that Dasatinib is authorized for sale in Canada. In cases of drug shortages, Health Canada may permit exceptional importation and sale of designated drugs.
• Estimated Timeline for Registration: Timelines can vary; during shortages, the exceptional importation process may expedite access.
• Import Tariff/Duty for HS 30049049: Import duties for pharmaceuticals are generally low or exempt; specific rates should be confirmed with the Canada Border Services Agency.

• Australia:
• Regulatory Authority: Therapeutic Goods Administration (TGA).
• Import Registration Process: Dasatinib must be registered in the Australian Register of Therapeutic Goods (ARTG). Importers need to provide evidence of compliance with TGA standards, including quality, safety, and efficacy.
• Estimated Timeline for Registration: The registration process can take several months, depending on the completeness of the application and TGA's assessment workload.
• Import Tariff/Duty for HS 30049049: Pharmaceuticals are typically subject to low tariffs; exact rates should be verified with the Australian Border Force.

• Mexico:
• Regulatory Authority: Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).
• Import Registration Process: Importers must obtain a sanitary registration from COFEPRIS, demonstrating that Dasatinib meets Mexican health regulations.
• Estimated Timeline for Registration: The process can take several months, influenced by the complexity of the application and COFEPRIS's review schedule.
• Import Tariff/Duty for HS 30049049: Tariff rates should be confirmed with the Mexican Tax Administration Service (SAT), as they may vary.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
• Import Registration Process: Dasatinib must be authorized for the Belgian market, requiring compliance with FAMHP regulations, including quality, safety, and efficacy standards.
• Estimated Timeline for Registration: The registration process can take several months, depending on the application details and FAMHP's review process.
• Import Tariff/Duty for HS 30049049: As part of the European Union, Belgium applies the EU's Common External Tariff; specific rates should be verified with Belgian Customs.

Importers are advised to consult the respective regulatory authorities and customs agencies for the most current and detailed information.

The demand for Dasatinib in importing countries is influenced by several factors:

• Disease Prevalence: Dasatinib is primarily used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The prevalence of these conditions directly impacts demand. For instance, the American Cancer Society estimated that in 2025, approximately 8,450 new cases of CML would be diagnosed in the United States, indicating a steady need for effective treatments like Dasatinib.

• Government Healthcare Programs and Universal Health Coverage Expansion: Countries expanding universal health coverage and enhancing oncology treatment programs contribute to increased demand. For example, Australia's Pharmaceutical Benefits Scheme (PBS) subsidizes medications like Dasatinib, making them more accessible to patients and thereby driving demand.

• WHO Essential Medicines List Procurement and Tender-Based Purchasing: Dasatinib's inclusion in the World Health Organization's List of Essential Medicines underscores its importance in cancer treatment. This designation encourages procurement by government and international health organizations through tender-based purchasing, ensuring broader access and consistent demand.

With 177 buyers across 71 countries, the global market for Dasatinib reflects a robust and diverse demand landscape, presenting significant opportunities for suppliers to meet the needs of various healthcare systems.

The importation of Dasatinib from India involves various buyer segments, each with distinct purchasing behaviors:

• Pharmaceutical Companies: Entities like TARO PHARMACEUTICALS INC (Canada), DR. REDDY'S LABORATORIES INC (United States), and AUROBINDO PHARMA USA INC (United States) are prominent buyers. These companies procure Dasatinib to expand their oncology portfolios, ensuring a steady supply to meet market demand. Their purchasing patterns typically involve large, consistent orders to maintain inventory levels and fulfill contractual obligations.

• Distributors: Organizations such as YUSEN LOGISTICS BENELUX BELGIUM (Belgium) function as intermediaries, facilitating the distribution of Dasatinib to various healthcare providers. Their procurement is characterized by bulk purchases, aligning with market demand and distribution agreements.

• Healthcare Providers: Entities like SUN PHARMA ANZ PTY LTD (Australia) may represent hospital groups or healthcare networks that import Dasatinib directly to ensure timely availability for patient treatment. Their buying behavior is influenced by patient needs, treatment protocols, and budget considerations, often resulting in periodic, substantial orders.

• Government Procurement Agencies: Organizations such as NUEVOS ETICOS NEOETHICALS S A (Guatemala) may engage in tender-based purchasing to supply public healthcare systems. Their procurement processes are typically governed by national healthcare policies, budget allocations, and the objective of providing affordable medications to the population.

Understanding these segments is crucial for tailoring market strategies, forecasting demand, and ensuring efficient supply chain management.

Import regulations for Dasatinib vary across the top importing countries:

• United States:
• Regulatory Authority: Food and Drug Administration (FDA).
• Import Registration Process: Importers must ensure that Dasatinib complies with FDA regulations, including proper labeling and registration. Affirmation of Compliance codes, such as Drug Registration Number (REG) and Drug Listing Number (DLS), are required to facilitate the import process.
• Estimated Timeline for Registration: The timeline can vary; however, providing accurate Affirmation of Compliance codes can expedite the initial screening and review process.
• Import Tariff/Duty for HS 30049049: Specific tariff rates for this HS code should be verified with the U.S. International Trade Commission or Customs and Border Protection, as they are subject to change.

• Canada:
• Regulatory Authority: Health Canada.
• Import Registration Process: Importers must comply with the Food and Drug Regulations, ensuring that Dasatinib is authorized for sale in Canada. In cases of drug shortages, Health Canada may permit exceptional importation and sale of designated drugs.
• Estimated Timeline for Registration: Timelines can vary; during shortages, the exceptional importation process may expedite access.
• Import Tariff/Duty for HS 30049049: Import duties for pharmaceuticals are generally low or exempt; specific rates should be confirmed with the Canada Border Services Agency.

• Australia:
• Regulatory Authority: Therapeutic Goods Administration (TGA).
• Import Registration Process: Dasatinib must be registered in the Australian Register of Therapeutic Goods (ARTG). Importers need to provide evidence of compliance with TGA standards, including quality, safety, and efficacy.
• Estimated Timeline for Registration: The registration process can take several months, depending on the completeness of the application and TGA's assessment workload.
• Import Tariff/Duty for HS 30049049: Pharmaceuticals are typically subject to low tariffs; exact rates should be verified with the Australian Border Force.

• Mexico:
• Regulatory Authority: Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).
• Import Registration Process: Importers must obtain a sanitary registration from COFEPRIS, demonstrating that Dasatinib meets Mexican health regulations.
• Estimated Timeline for Registration: The process can take several months, influenced by the complexity of the application and COFEPRIS's review schedule.
• Import Tariff/Duty for HS 30049049: Tariff rates should be confirmed with the Mexican Tax Administration Service (SAT), as they may vary.

• Belgium:
• Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
• Import Registration Process: Dasatinib must be authorized for the Belgian market, requiring compliance with FAMHP regulations, including quality, safety, and efficacy standards.
• Estimated Timeline for Registration: The registration process can take several months, depending on the application details and FAMHP's review process.
• Import Tariff/Duty for HS 30049049: As part of the European Union, Belgium applies the EU's Common External Tariff; specific rates should be verified with Belgian Customs.

Importers are advised to consult the respective regulatory authorities and customs agencies for the most current and detailed information.

The demand for Dasatinib in importing countries is influenced by several factors:

• Disease Prevalence: Dasatinib is primarily used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The prevalence of these conditions directly impacts demand. For instance, the American Cancer Society estimated that in 2025, approximately 8,450 new cases of CML would be diagnosed in the United States, indicating a steady need for effective treatments like Dasatinib.

• Government Healthcare Programs and Universal Health Coverage Expansion: Countries expanding universal health coverage and enhancing oncology treatment programs contribute to increased demand. For example, Australia's Pharmaceutical Benefits Scheme (PBS) subsidizes medications like Dasatinib, making them more accessible to patients and thereby driving demand.

• WHO Essential Medicines List Procurement and Tender-Based Purchasing: Dasatinib's inclusion in the World Health Organization's List of Essential Medicines underscores its importance in cancer treatment. This designation encourages procurement by government and international health organizations through tender-based purchasing, ensuring broader access and consistent demand.

With 177 buyers across 71 countries, the global market for Dasatinib reflects a robust and diverse demand landscape, presenting significant opportunities for suppliers to meet the needs of various healthcare systems.